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Meclizine-induced enhanced 
glycolysis is neuroprotective in 
Parkinson disease cell models
Chien Tai Hong1,2, Kai-Yin Chau1 & Anthony H. V. Schapira1
Meclizine is a well-tolerated drug routinely used as an anti-histamine agent in the management of 
disequilibrium. Recently, meclizine has been assessed for its neuroprotective properties in ischemic 
stroke and Huntington disease models. We found that meclizine protected against 6-hydroxydopamine-
induced apoptosis and cell death in both SH-SY5Y cells and rat primary cortical cultures. Meclizine 
increases the level of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which 
activates phosphofructokinase, a rate-determining enzyme of glycolysis. This protection is therefore 
mediated by meclizine’s ability to enhance glycolysis and increase mitochondrial hyperpolarization. 
Meclizine represents an interesting candidate for further investigation to re-purpose for its potential to 
be neuroprotective in Parkinson disease.
Parkinson disease (PD) is the second most common neurodegenerative disease1. The pathological hallmark of 
PD is the degeneration of dopaminergic neurons in the midbrain substantia nigra (SN) with Lewy body deposi-
tion2. Clinically, PD leads to motor and non-motor symptoms, due to both dopaminergic and non-dopaminergic 
deficits that result in disability and a significant reduction in quality of life3. Although several of symptomatic 
treatments are available, there is no therapy able to slow disease progression.
Mitochondrial dysfunction is recognized as a significant feature of PD pathogenesis4–6. In addition to their 
role in bioenergetics, mitochondria are involved in mediating apoptosis. Several apoptotic markers, including 
Bax, caspase 9 and caspase-3 have been identified in SNpc of PD7–10. Increased reactive oxygen species (ROS) 
and depolarization of the mitochondrial membrane potential (ψ m ) are believed to trigger the intrinsic apoptotic 
pathway by increasing the mitochondrial outer membrane permeability (MOMP). Release of mitochondrial pro-
teins including cytochrome c, takes place after MOMP and initiate the apoptotic cell death cascade11.
In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and β -amyloid toxicity models, increased glyc-
olysis has been suggested to be able to restore cellular ATP synthesis, control ROS production, and maintain ψ m 
in order to protect cell death12–17. Meclizine, is a widely-used antiemetic, and has been shown to enhance glycol-
ysis and protect against neuronal death in stroke and Huntington disease models18,19.
In the present study, we demonstrate the neuroprotective effect of meclizine in cell models of PD. Our data 
show that the protective mechanism of meclizine involves increased glycolysis without altering oxidative phos-
phorylation and total ATP levels, the maintenance of mitochondrial hyperpolarization and the inhibition of 
apoptosis. We found that meclizine enhances glycolysis by increasing the activity 6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase 3 (PFKFB3) activity, which mediates the synthesis of fructose 2,6-bisphosphate to 
activate phosphofructokinase.
Results
Meclizine protected 6-OHDA induced apoptosis and cell death in primary cortical neu-
rons. The protection of meclizine was tested in primary rat cortical cultures highly enriched with neurons 
(supplementary S1). 6-OHDA induced a dose-dependent increase of Fluoro-jade C (FJ-C) stain, which reflected 
the neuronal death (supplementary S2A,B). The concentration of 10 μ M 6-OHDA was chosen because of remark-
able but not overwhelming effect of cell death (21.10 ± 5.37% FJ-C stained cells compared with no-toxin con-
trol: 6.65 ± 0.67% FJ-C stained cells). Compared with control, 3.125 μ M of meclizine treatment, which was 
determined by the dose-dependent experiments of the protection of meclizine against 6-OHDA (supplemen-
tary S2C), for 24 hours did not increase the neuronal death detected by FJ-C stain. Upon 10 μ M of 6-OHDA 
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treatment for 24 hours, 3.125 μ M meclizine significantly reduced the neuronal death release from 20.38 ± 1.57% 
to 12.68 ± 0.74% (p < 0.001) (Fig. 1A). The protection of meclizine was also confirmed by the LDH release assay: 
upon 10 μ M of 6-OHDA treatment for 24 hours, 3.125 μ M meclizine significantly reduced LDH release from 
10.8 ± 1.4% to 6.8 ± 0.9% (p < 0.05) (Fig. 1B). Propidium iodide binding assay confirmed the protection by 
meclizine in primary rat cortical cultures (Fig. 1C).
To determine whether the prevention of cell loss by meclizine is an outcome of inhibiting apoptosis, we 
assessed caspase-3 activation upon 6-OHDA treatment. 6-OHDA is known to induce apoptosis and caspase-3 
activation20. In primary rat cortical culture cells, apoptotic cells were identified by positive immunocytochemistry 
of cleaved caspase-3 (Supplementary S2D). In basal conditions, 3.125 μ M of meclizine did not increase spontane-
ous apoptosis. Pre-treatment with 3.125 μ M of meclizine for 24 hours before 20 μ M of 6-OHDA for 6 hours sig-
nificantly reduced the percentage of neurons with positive cleaved caspase-3 immunostaining from 12.4 ± 0.6% 
in the non-meclizine treated group to 8.8 ± 0.4% (p < 0.001) (Fig. 1D).
Meclizine protected apoptosis and death in PD cellular model. SH-SY5Y cells are widely used as a 
dopaminergic cell model and express the dopamine transporter and dopamine synthesis capacity. Meclizine treat-
ment alone up to 12.5 μ M for 48 hours did not induce cell death in SH-SY5Y cells. Upon 30 μ M of 6-OHDA treat-
ment for 48 hours, co-treatment with an increasing level of meclizine up to 12.5 μ M produced a dose-dependent 
reduction of LDH release in SH-SY5Y cells; this became significant at 3.125 μ M and 12.5uM, from 20.6 ± 1.2% 
to 13.3 ± 0.6 and 12.2 ± 0.4%% respectively (Fig. 2A). The anti-apoptotic effect of meclizine was also evaluated in 
SH-SY5Y cells. Meclizine treatment at 12.5 μ M for 24 hours alone did not alter the caspase-3 activity. SH-SY5Y 
cells pre-treated with 12.5 μ M of meclizine for 24 hours significantly down-regulated the activation of caspase-3 
induced by 6-OHDA by 19% (Fig. 2B).
Meclizine hyperpolarized mitochondria and prevented the depolarization induced by 
6-OHDA. 6-OHDA causes increased ROS production and this can be measured as a significant fall in 
Figure 1. Meclizine protected 6-hydroxydopamine (6-OHDA) induced apoptosis and death in primary 
rat cortical cultures. (A) primary rat cortical cultures enriched with neurons, 3.125 μ M meclizine treatment 
for 24 hours did not increase the spontaneous neuronal death but significantly reduced the percentage of FJ-C 
positive cells against 10 μ M 6-OHDA treatment for 24 hours (control: 20.4 ± 1.6%, meclizine: 12.7 ± 0.7%, 
p < 0.001, n = 10). Meclizine was applied at the same time with 6-OHDA. (N.S., non-significant, ***p < 0.001). 
(B) In primary rat cortical cultures enriched with neurons treated with 10 μ M 6-OHDA for 24 hours, 3.125 μ M 
meclizine co-treatment significantly protected against cytotoxicity (control: 10.8 ± 1.4%, meclizine: 6.8 ± 0.9%, 
*p < 0.05, n = 8). Meclizine alone did not produce extra cell death. (C) The protection of meclizine against 
10 μ M 6-OHDA treatment on rat primary cortical culture cells for 24 hours was confirmed by PI binding assay 
(control: 11.5 ± 0.7%, meclizine: 6.6 ± 0.7%, p < 0.001, n = 10). Data were presented as mean ± S.E.M. and 
statistic analysis was performed by two-tailed Student’s t-test. (N.S., non-significant, ***p < 0.001). (D) In 
primary rat cortical cultures treated with 20 μ M 6-OHDA for 6 hours, pre-treatment with 3.125 μ M meclizine 
for 24 hours significantly decreased the percentage of apoptotic cells induced by 6-OHDA (control: 12.4 ± 0.6%, 
meclizine: 8.8 ± 0.4%, ***p < 0.001, n = 10).
www.nature.com/scientificreports/
3Scientific RepoRts | 6:25344 | DOI: 10.1038/srep25344
aconitase activity (see supplementary S3)21. Meclizine’s mechanism of action did not include any protection of 
aconitase, implying that it is not an anti-oxidant (supplementary S4). 6-OHDA also causes a fall in ψ m and pre-
vention of this is considered anti-apoptotic12,22. ψ m was measured by TMRM fluorescence with adjustment for 
mitochondrial content. In rat primary cortical neurons, we found that 1 μ M of meclizine treatment for 48 hours 
increased net fluorescence of TMRM compared with control, which reflects the mitochondrial hyperpolarization. 
Meanwhile, meclizine treatment on rat primary cortical neurons prevented 6-OHDA induced depolarization on 
rat primary cortical neurons, which would favour an anti-apoptotic action (Fig. 3A,B). In similar, we noticed that 
meclizine at 12.5 μ M not only induced a 32% increase (p < 0.001) in ψ m in SH-SY5Y cells, but also prevented 
100 μ M 6-OHDA treatment for one hour induced mitochondrial depolarization and maintained ψ m at basal 
levels (Fig. 3C,D).
Mitochondrial hyperpolarization and anti-apoptotic effect of meclizine are due to increased 
glycolysis. SH-SY5Y cells treated with 12.5 μ M meclizine for 48 hours significantly increased the glyco-
lytic activity as measured by extracellular acidification rate, by 157% (p < 0.01) (Fig. 4A). This was confirmed 
by the use of glycolytic inhibitors 2-deoxy-D-glucose (2DG) and 3-bromopyruvate (3BP) that blocked the 
meclizine-induced increase in glycolysis (Fig. 4A). The increase in glycolysis did not affect oxidative phosphoryl-
ation or total ATP levels (supplementary S4).
10 μ M of 2DG or 5 μ M of 3BP prevented the mitochondrial hyperpolarization seen with meclizine treat-
ment (Fig. 4B). Lastly, we investigated whether the meclizine-mediated neuroprotection against 6-OHDA is 
glycolysis-dependent in SH-SY5Y cells. LDH release measurements showed that 10 μ M of 2DG or 5 μ M of 3BP 
did not alter the cytotoxicity produced by 6-OHDA at 30 μ M treated for 48 hours. In line with the data shown 
in Fig. 1A, co-treatment with 12.5 μ M meclizine significantly decreased the LDH release induced by 6-OHDA. 
However, co-administration with the glycolytic inhibitors resulted in significant attenuation of protection against 
6-OHDA (Fig. 4C).
Meclizine enhanced glycolysis through increased levels of PFKFB3. An increase in glycolysis 
may be HIF-1α -dependent, but levels of this protein were not increased with meclizine treatment (Fig. 5A). 
Alternatively, increased expression of glycolytic enzymes can also enhance glycolysis, but we found that 12.5 μ M 
meclizine treatment for 48 hours did not alter the protein levels of: HK1, HK2, PFK and PKM1/2 (Fig. 5B).
Figure 2. Meclizine protected apoptosis and cell death in PD cellular model. (A) In SH-SY5Y cells treated 
with 30 μ M 6-OHDA for 48 hours, meclizine co-treatment exhibited a dose-dependent protection against 
cytotoxicity (as indicated by percentage LDH release). Meclizine at 3.125 μ M and 12.5 μ M produced significant 
protection (control: 20.6 ± 1.2%, 3.125 μ M : 13.3 ± 0.6%, 12.5 μ M:12.2 ± 0.4%, ***p < 0.001, n = 8). In 
addition, the maximum meclizine dose alone did not lead to cell death. (B) In SH-SY5Y cells treated with 
100 μ M 6-OHDA for 8 hours, pre-treatment with 12.5 μ M meclizine for 24 hours significantly reduced 6-OHDA 
induced increased caspase-3 activity (control: 1148 ± 37%, meclizine:937 ± 47%, **p < 0.01, n = 7).
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PFKFB is a bifunctional enzyme that can catalyze the conversion of fructose-6-phosphate to fructose 
2,6-bisphosphate (F2,6 P2) and vice versa. PFKFB Isoform 3 predominately effects the synthesis of F2, 6 P2, which 
is a powerful allosteric activator of PFKP and glycolysis23. 12.5 μ M meclizine treatment for 48 hours significantly 
increased the protein level of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) in SH-SY5Y 
cells (139.5 ± 12.3%, p < 0.01). 100 μ M 6-OHDA treatment for 6 hours on control SH-SY5Y cells resulted in a 
reduction of PFKFB3 protein level (96.3 ± 6.0%) while pre-treatment of 12.5 μ M meclizine for 48 hours prevented 
the reduction of PFKFB3 protein level caused by 6-OHDA (106.2 ± 5.5%) (Fig. 5C,D). These effect was seen on 
rat primary cortical neurons as well (Supplementary S5).
Discussion
The present study demonstrates that meclizine, a glycolysis-enhancing agent, protects neuronal death in the 
6-OHDA cell toxicity model. Meclizine hyperpolarizes mitochondria to prevent 6-OHDA induced apoptosis 
and mitochondrial depolarization and these effects are reduced by inhibition of meclizine-induced glycolysis. 
Meclizine increases glycolysis through increased levels of PFKFB3, which activates the key enzyme, PFK to 
enhance glycolysis.
Glycolysis is less efficient for ATP synthesis than oxidative phosphorylation. Neurons predominantly rely 
on oxidative phosphorylation for ATP generation and are not able to up-regulate glycolysis under respiratory 
inhibition24. However, it has been reported that glycolysis is responsible for neuronal vesicle transport in axonal 
Figure 3. Meclizine hyperpolarized mitochondria and prevented 6-OHDA induced depolarization.  
(A,B) Representative images of TMRM staining on rat primary cortical neurons and the illustration of the 
change of net TMRM fluorescence intensity (RFU) under meclizine and 6-OHDA treatment. Rat primary 
cortical neurons pre-treated with 1 μ M meclizine for 24 hours demonstrated remarkable higher net TMRM 
fluorescence intensity compared with control. Sham injection did not affect the net TMRM fluorescence 
intensity. 30 μ M 6-OHDA was applied to the cells at 390 seconds and reduced the net TMRM fluorescence 
intensity was noted in both control and meclizine pre-treated neurons. However, meclizine pre-treated rat 
primary cortical neurons still exhibited higher net TMRM fluorescence intensity than the baseline of control 
neurons. Control and meclizine pre-treated TMRM staining images were acquired at 300 seconds and the 
6-OHDAt-treated images in both conditions were acquired at 600 seconds. The net TMRM fluorescence was 
measured by the total TMRM fluorescence minus the background TMRM fluorescence. Data were presented as 
mean ± S.E.M. and the n = 5. (C,D) Representative images of TMRM staining of SH-SY5Y cells under different 
conditions and analysis of TMRM fluorescence intensity to produce a percentage of mitochondrial membrane 
potential (Ψ m). Pre-treating SH-SY5Y cells with 12.5 μ M meclizine for 48 hours significantly hyperpolarized 
mitochondria (control: 100.0 ± 1.5%, meclizine:132.8 ± 6.1%, ***p < 0.001, n = 10) and significantly prevented 
the mitochondrial depolarization induced by 100 μ M 6-OHDA for 1 hour (control: 77.0 ± 2.8%, meclizine: 
101.5 ± 4.0%, ***p < 0.001, n = 10).
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regions25. In the present study, meclizine increases glycolysis but does not induce apoptosis and cell death in neu-
ronal cells, which also support the notion that increasing glucose metabolism by glycolysis does not compromise 
the neuronal cells.
In the present study, meclizine increased cellular glycolysis, hyperpolarized mitochondria and protected 
against 6-OHDA toxicity. These effects were prevented by glycolysis inhibitors. Although hyperpolarization is 
also able to result from complex V inhibition, it is unlikely that meclizine hyperpolarizes mitochondria through 
this mechanism because complex V inhibition blocks oxidative phosphorylation and is toxic to the cells, whereas 
we saw no cytotoxicity upon meclizine treatment.
6-OHDA induces oxidative damage and apoptotic cell death and is widely-used in experimental PD models. 
Mitochondrial depolarization is a universal and early phenomenon of 6-OHDA induced apoptosis26–28. Meclizine 
enhanced glycolysis by increasing levels of PFKFB3 and protects against the fall in ψ m induced by 6-OHDA treat-
ment and initiation of the caspase cascade.
We have demonstrated that the anti-emetic meclizine increases glycolysis by increasing the levels of PFKFB3. 
This shift in energy metabolism is able to protect against the fall in ψ m induced by 6-OHDA and reduce apoptotic 
cell death. We suggest that these results support further evaluation and potential re-purposing of meclizine as a 
modulator of energy metabolism for neuroprotection in PD.
Material and Methods
Cell models and treatments. SH-SY5Y cells were maintained as previously described29 with reagents sup-
plied from Life Technologies (Paisley, UK). The method for setting up E18 primary rat cortical cultures enriched 
with neurons was adapted from previous well-established protocols30, and they were used 7 days post-culture. 
Meclizine was obtained from 2 independent sources namely Tocris Bioscience (Bristol, UK) and Santa Cruz 
Biotechnology(Heidelberg, Germany), and was dissolved in DMSO to produce a 12.5 mM stock. 6-hydroxydopa-
mine (6-OHDA) was purchased from Sigma-Aldrich (Dorset, UK).
Figure 4. Mitochondrial hyperpolarization and prevention of cell death upon meclizine treatment in 
SH-SY5Y cells was resulted from increased glycolysis. (A) 12.5 μ M meclizine for 48 hours significantly up-
regulated the glycolytic activity as shown by extracellular acidification rate (ECAR) measured by XF analyzer. 
However, co-administration with glycolytic inhibitor, either 10 μ M of 2-deoxy-glucose (2DG) or 5 μ M of 
3-Bromopyruvate (3BP) markedly reduced the enhancement of glycolysis. (control: 1405 ± 204, meclizine: 
3613 ± 544, **p < 0.01; 2DG: 2359 ± 291, 3BP: 1856 ± 332 mpH/min/μ g, p = 0.08 and 0.009, respectively, 
n = 6) (B) 10 μ M of 2DG and 5 μ M of 3BP alone did not affect the ψ m. However, applying either glycolytic 
inhibitors significantly attenuated the mitochondrial hyperpolarization induced by 12.5 μ M meclizine for 
48 hours (meclizine: 135 ± 6.2%, meclizine+ 2DG: 107 ± 1.9%, meclizine+ 3BP: 119 ± 2.9%, ***p < 0.001 
and *p < 0.05, respectively, n = 8). (C) Co-administration of either 10 μ M of 2DG or 5 μ M of 3BP, attenuated 
or reversed the protection of LDH release from meclizine against 30 μ M 6-OHDA for 48 hours (meclizine: 
11.8 ± 0.3%, meclizine+ 2DG: 16.0 ± 1.1%; meclizine+ 3BP: 25.8 ± 1.3%, *p < 0.05 and ***p < 0.001, 
respectively, n = 8).
www.nature.com/scientificreports/
6Scientific RepoRts | 6:25344 | DOI: 10.1038/srep25344
Protein analysis. Whole cell lysates for Western blot analysis were prepared in 10 mM Tris–HCl pH 
7.5, 0.1% of SDS and in the presence of protease inhibitors (Fisher Scientific, Loughborough, UK), followed 
by DNAse I digestion (Promega, Southampton, UK). Protein samples were separated under reducing condi-
tions by SDS-PAGE using the Novex system (Life Technologies), transferred to PVDF (Millipore, Watford, UK) 
and were analyzed by a standard Western blot protocol using Amersham ECL Western Blotting Detection 
Reagent and Amersham Hyperfilm (GE Healthcare, Little Chalfont, UK). The following antibodies were used: 
anti-PFKFB3 antibody, anti-hypoxia inducible factor (HIF)-1α antibody, anti-phosphofrctokinase (PFK) anti-
body, anti-pyruvate kinase (PK) antibody, and hexokinase 1 and 2 antibody (HK1 & 2) (New England Biolabs, 
Hitchin, UK ). Expression level of the above targets was corrected by the level of β -actin and normalized to 
non-treatment (NT) that is set as 100%.
Protein concentration was determined by bicinchoninic acid assay (BCA) according to manufacturer’s 
instructions (Fisher Scientific).
Apoptosis and cell death analysis. Caspase-3 activity was measured from cell lysates according to 
the manufacturer’s instruction of the EnzChek® Caspase-3 Assay Kit #2 (Life Technologies) which has been 
described previously31. The caspase-3 activity was corrected by the total protein level of the cell lysate and nor-
malized to non-treatment (NT) that is set as 100%. Apoptotic cells in primary rat cortical culture were identified 
by immunocytochemistry using the anti-cleaved caspase-3 antibody (New England Biolabs) followed by Alexa 
Fluor-568 secondary antibody (Life Technologies), and mounted with Citifluor (London, UK) in the presence 
of DAPI. Fluorescent images were obtained by the Axioplan epifluorescent microscope (Zeiss, Cambridge, UK), 
from which positive stained and total number of cells were counted to produce a percentage of apoptotic cells. 
Lactate dehydrogenase (LDH) release assay (Roche, Burgess Hill, UK) was used to quantify the cell death and the 
protocols had been described32. The percentage LDH release was obtained from the experimental to the Triton 
X-100 treated total release. For the detection of neuronal death in primary culture, cells were stained with 0.001% 
Fluoro-Jade C (FJ-C)(Millipore) after fixed with 4% paraformaldehyde. Positive stained cells were counted under 
by epifluorescent microscope by examiner blinded to the condition.
Ψm analysis. Maximal steady state mitochondrial fluorescence upon Tetramethylrhodamine, methyl ester 
(TMRM, Life Technologies) staining at 25 nM was measured from <1.5μ m confocal images obtained from 
the Zeiss 510 laser scanning microscope after z-projection, as previously described33,34. Images obtained from 
SH-SY5Y cells were analyzed by ImageJ software (National Institutes of Health, Maryland, USA) following 
Figure 5. Increased glycolysis upon meclizine treatment was associated with increased PFKFB3 in SH-
SY5Y cells. (A) Representative Western blot images demonstrate that meclizine treatment at 12.5 μ M for 
48 hours did not increase the protein level of hypoxia-inducible factor 1α (HIF-1α ). (B) Representative Western 
blot images support that meclizine treatment at 12.5 μ M for 48 hours did not alter the protein level of certain 
key glycolytic enzymes, including hexokinase 1 (HK1), hexokinase 2 (HK2), phosphofructokinase (PFKP), 
and pyruvate kinase isozymes M1/M2 (PKM1/2). (C,D) Representative Western blot images and densitometry 
analysis revealed that 12.5 μ M meclizine treatment for 48 hours significantly increased the protein level of 
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) in SH-SY5Y cells (139.5 ± 12.3%, p < 0.01). 
100 μ M 6-OHDA treatment for 6 hours on control SH-SY5Y cells resulted in a slight reduction of PFKFB3 
protein level (96.3 ± 6.0%). Pre-treatment of meclizine prevents the reduction of PFKFB3 protein level caused 
by 6-OHDA (106.2 ± 5.5%). The protein expression amount was normalized by control SH-SY5Y cells. Data 
were presented as mean ± S.E.M. and the n = 6, **p < 0.01.
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previously described analysis protocols35. Briefly, raw images were background corrected, linearly contrast opti-
mized, applied with a 7 × 7 ‘top hat’ filter, subjected to twice 3 × 3 median filter, and then threshold, to generate 
binary images. Mitochondrial content per cell was estimated based on mitochondrial occupancy of these binary 
images. Mitochondrial fluorescence of each cell from the background corrected images was corrected by the 
mitochondrial content to produce the Ψ m.
For the rat primary cortical neurons, net TMRM fluorescence is obtained by the total TMRM fluorescence 
minus the background TMRM fluorescence.
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR).
OCR and ECAR were measured by the XF extracellular flux analyzer following manufacturer’s instructions 
(Seahorse Bioscience, MA, US). For measuring OCR, 25 mM glucose, 1 μ g/ml oligomycin and 2 μ M rotenone 
were loading sequentially whereas for ECAR, 25 mM glucose, 1 μ g/ml oligomycin and 100 μ M 2DG were applied.
Aconitase assay. Aconitase enzymatic activities were measured as described36, subsequently activity was 
corrected by protein amount.
Total ATP measurement. Total ATP was measured using the ATP Bioluminesence Assay kit CLSII (Roche, 
Mannhein, Germany), from the cell lysates and that was corrected by the protein level.
Statistics. All data were presented as mean ± standard error of mean (S.E.M.). Statistics was performed by 
either two-tailed Student’s t- test or one-way ANOVA with post-hoc analysis. p value less than 0.05 is considered 
as statistically significant.
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